Fagan Associates’s Sarepta Therapeutics SRPT Stock Holding History

Fagan Associates’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,170	Closed	-$938K	–	118
2019 Q2	$938K	Buy	+6,170	New	+$750K	0.38%	67

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fagan Associates's SRPT Position: Q3 2019 in Review

Fagan Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 6,170 shares — an estimated $938K sold.

Fagan Associates first reported a position in SRPT in Q2 2019 and held it in 1 quarter. The position peaked at $938K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Fagan Associates reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Fagan Associates sold 6,170 Sarepta Therapeutics shares in Q3 2019, an estimated $938K.
Fagan Associates first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 1 quarter.
Fagan Associates's Sarepta Therapeutics position peaked at $938K in Q2 2019.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Fagan Associates's 13F filing for Q3 2019, filed 13 Nov 2019.